Several PTP1B inhibitors, including ertiprotafib, trodusquemine and ABBV-CLS-484, have, however, successfully reached phase I and II clinical trials for the treatment of diabetes and obesity, and new, highly specific therapeutic PTP1B inhibitors continue to be explored [16,17]. Here, PTPN1 is linked to obesity disorder.